Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Papaverine is an opium alkaloid antispasmodic drug primarily used to treat visceral spasms and vasospasms, including those involving the intestines, heart, or brain. It is also occasionally used in the treatment of erectile dysfunction and acute mesenteric ischemia. Unlike other opium alkaloids such as morphine, papaverine does not have analgesic properties and differs structurally and pharmacologically from them. Its main mechanism of action involves direct smooth muscle relaxation by inhibiting phosphodiesterases (notably cAMP and cGMP phosphodiesterase), leading to increased intracellular levels of cAMP and cGMP, which results in vasodilation. Papaverine may also inhibit calcium ion channels in smooth muscle cells. It is approved for use as a vasodilator to improve blood flow in conditions associated with poor circulation or vascular spasm.[1][2][3][5][6]. Recent research has shown that papaverine can act as a radiosensitizer for hypoxic tumors by inhibiting mitochondrial complex I[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on papaverine.